We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00429962
First Posted: February 1, 2007
Last Update Posted: April 7, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
University Hospital, Basel, Switzerland
  Purpose
This pilot study is designed to evaluate the safety and efficacy of intravitreal ranibizumab used in combination with verteporfin photodynamic therapy (Visudyne®) compared to ranibizumab monotherapy for the treatment of subfoveal CNV secondary to AMD

Condition Intervention Phase
Choroidal Neovascularization Age-Related Macular Degeneration Drug: intravitreal ranibizumab Drug: intravitreal ranibizumab & photodynamic therapy Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Randomized, Phase IIIb Study Comparing Safety, Tolerability and Efficacy Between Lucentis® Administered in Conjunction With PDT With Visudyne® and Lucentis® in Patients With Subfoveal CNV Secondary to Age-Related Macular Degeneration

Resource links provided by NLM:


Further study details as provided by University Hospital, Basel, Switzerland:

Primary Outcome Measures:
  • First injection with PDT [ Time Frame: monthly ]

Secondary Outcome Measures:
  • Monthly clinical evaluation of safety and necessity of re-intravitreal injection of ranibizumab after three initial injections [ Time Frame: monthly ]

Enrollment: 40
Study Start Date: July 2006
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
intravitreal ranibizumab used in combination with verteporfin photodynamic therapy
Drug: intravitreal ranibizumab & photodynamic therapy
intraocular injection photodynamic treatment (LASER) after intravenous injection
Other Name: Visudyne
Active Comparator: B
intravitreal ranibizumab
Drug: intravitreal ranibizumab
intraocular injection
Other Name: Lucentis

Detailed Description:
Intravitreal ranibizumab has shown to increase average vision in patients with subfoveal CNV secondary to AMD. However, the treatment does not provide benefit to all patients and the treatment regimen requires monthly intravitreal injections. Ranibizumab is an anti-VEGF-A monoclonal antibody fragment. Verteporfin photodynamic therapy acts through occluding newly formed vessels. The combination of these therapies acting through different modes of action bears the potential to provide a more convenient and less frequent therapy while maintaining/improving the increase in vision improvement observed with ranibizumab monotherapy. The strategic goal is to evaluate whether intravitreal ranibizumab in combination with verteporfin photodynamic therapy is an effective, safe and convenient treatment for patients with subfoveal CNV secondary to AMD and explore potential advantages of such treatment compared to ranibizumab monotherapy
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years to 95 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. patients over 50 years, subfoveal CNV of any type secondary to age-related macular degeneration (AMD), no "macula-treatment for the last 30 days (e.g. with PDT, TA, Laser, Macugen®).

    • the area of the CNV must occupy at least >50% of the lesion (total lesion size under 5400 microns in greatest linear dimension)
    • Occult CNV:

      • recent disease progression
      • bleeding
      • VA decreased the last three months >5 letters or 2 or more than two lines (Snellen)
      • 10% increase of the lesion size the last three months
  2. Best corrected visual acuity score between 24-73 letters (20/40 to 20/320) (ETDRS 4 m)

Exclusion Criteria:

  1. Prior treatment with mit Laser, PDT, Macugen, TA
  2. Prior treatment with radiatio, vitrectomy, transpupillary thermotherapy
  3. History of surgical intervention in the study eye within two months preceding day 1
  4. concurrent use of systemic anti-VEGF agents
  5. previous treatment with or participation in a clinical trial involving anti-angiogenic drugs (Pegaptanib, ranibizumab, anecortave acetate of corticosteroids).
  6. Ocular disorders in the study eye that may confound interpretation of the study results, including retinal detachment or macular hole (Stage 3 or 4), active intraocular inflammation (grade trace or above) or persistent macular edema due to uveitis or other inflammatory diseases
  7. Retinal pigment epithelium tear, vitreous hemorrhage or history of rhegmatogenous retinal detachment or macular hole in the study eye
  8. History of idiopathic or autoimmune-associated uveitis in either eye, active infectious conjunctivitis, keratitis, scleritis or endophthalmitis in either eye
  9. Extracapsular extraction of cataract with phacoemulsification within two months preceding day 1, or a history of post-operative complications within the last 12 months preceding day 1 or a history of post-operative complications within the last 12 months preceding day 1 in the study eye (uveitis, cyclitis, iritis etc.)
  10. Glaucoma with IOP>25 mmHg despite therapy
  11. Aphakia or absence of the posterior capsule in the study eye
  12. Spherical equivalent >-8
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00429962


Locations
Switzerland
University Eye Clinic
Basel, Basel-Stadt, Switzerland, 4031
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Investigators
Study Director: Ulrike Schneider, MD University Eye Clinic Basel
  More Information

Responsible Party: Selim Orgul, University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier: NCT00429962     History of Changes
Other Study ID Numbers: 081-PRC-2006-005
First Submitted: January 31, 2007
First Posted: February 1, 2007
Last Update Posted: April 7, 2009
Last Verified: April 2009

Keywords provided by University Hospital, Basel, Switzerland:
subfoveal choroidal neovascularization (CNV)
age-related macular degeneration
ranibizumab monotherapy
combined verteporfin-therapy
Lucentis® (ranibizumab)
Visudyne®
photodynamic therapy

Additional relevant MeSH terms:
Macular Degeneration
Neovascularization, Pathologic
Choroidal Neovascularization
Retinal Degeneration
Retinal Diseases
Eye Diseases
Metaplasia
Pathologic Processes
Choroid Diseases
Uveal Diseases
Ranibizumab
Verteporfin
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents
Photosensitizing Agents
Dermatologic Agents